Aclaris Reports P-I (ATI-2138-PKPD-102) Trial Results of ATI-2138 for the Treatment of Immuno-Inflammatory Diseases
Shots:
- The P-I (ATI-2138-PKPD-102) multiple ascending dose (MAD) trial evaluating the safety, tolerability, PK, and PD of ATI-2138 (covalent ITK/JAK3 inhibitor) in 60 healthy patients across 6 dosing cohorts ranging from 10-80mg of total daily doses
- The results showed no serious AEs while the preliminary results from the MAD trial showed that ATI-2138 was well tolerated at all doses & had dose-proportional PK and dose-dependent inhibition of ITK and JAK3 exploratory PD biomarkers with near maximal inhibition achieved at 30mg total daily dose
- The company continues to advance the therapy in the P-IIa proof of concept study in patients with ulcerative colitis, and the trial is expected to initiate in early 2024
Ref: Globenewswire | Image: Aclaris
Related News:- Aclaris Enters into a License Agreement with Pediatrix for Developing and Commercializing ATI-1777 in Greater China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
